These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28903575)

  • 41. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
    Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
    Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
    Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
    Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Successful diagnosis of lymphoplasmacytic lymphoma with IgG paraprotein using MYD88 L265P mutation analysis].
    Abe M; Saburi M; Itani K; Kohno K; Soga Y; Kondo Y; Kawano Y; Nakayama T
    Rinsho Ketsueki; 2018; 59(6):695-697. PubMed ID: 29973445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical application of genomics in Waldenström macroglobulinemia.
    Branagan AR; Lei M; Treon SP; Castillo JJ
    Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
    Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
    Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
    [No Abstract]   [Full Text] [Related]  

  • 48. Current and Emerging Treatments for Waldenström Macroglobulinemia.
    Grimont CN; Castillo Almeida NE; Gertz MA
    Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
    Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
    Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.
    Albitar A; Ma W; DeDios I; Estella J; Agersborg S; Albitar M
    Int J Lab Hematol; 2016 Apr; 38(2):133-40. PubMed ID: 26797804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?
    Fang H; Kapoor P; Gonsalves WI; Frederick LA; Viswanatha D; Howard MT; He R; Morice WG; McPhail ED; Greipp PT; Ansell SM; Kyle RA; Gertz MA; Paludo J; Abeykoon J; King RL
    Am J Clin Pathol; 2018 Jul; 150(2):168-176. PubMed ID: 29868855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Waldenstrom macroglobulinemia: genetics dictates clinical course.
    Lenz G
    Blood; 2014 May; 123(18):2750-1. PubMed ID: 24786453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
    Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
    Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Successful detection of MYD88 L265P mutation in Waldenström's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].
    Nawata R; Sugiyama A; Harada K; Shinohara K; Yujiri T
    Rinsho Ketsueki; 2019; 60(8):903-909. PubMed ID: 31484887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
    Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
    Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
    Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
    Thomas SK
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 59. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.
    Jiménez C; Sebastián E; Chillón MC; Giraldo P; Mariano Hernández J; Escalante F; González-López TJ; Aguilera C; de Coca AG; Murillo I; Alcoceba M; Balanzategui A; Sarasquete ME; Corral R; Marín LA; Paiva B; Ocio EM; Gutiérrez NC; González M; San Miguel JF; García-Sanz R
    Leukemia; 2013 Aug; 27(8):1722-8. PubMed ID: 23446312
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation.
    Viscovo M; Clemmensen ML; Fosso F; Maiolo E; Autore F; Laurenti L; Hohaus S; Chiusolo P
    Int J Lab Hematol; 2024 Aug; 46(4):665-669. PubMed ID: 38390807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.